Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Veradermics Incorporated (MANE)

NYSE: MANE · Pharmaceutical Preparations · New Haven, CT

Our rating: Cautious

Cautious reaffirmed at $156.56, low conviction, November 11, 2026.

Breaks if: The Cautious call would be wrong if Veradermics reports a first full quarter of product revenue exceeding $50 million within the next two quarterly prints, or receives an FDA approval paired with early evidence of commercial traction — either outcome would give the $6.5 billion valuation a plausible anchor and shift the picture toward Neutral. Conversely, if annual free-cash-flow burn widens beyond $150 million without a concurrent financing announcement, the thesis deepens rather than breaks.

Key figures

Market value$5.0B
Revenue, last 12 monthsn/a
Net income, last 12 months−$94M
Free cash flow, last 12 months−$83M
Price to earningsn/a
Free cash flow yield−1.6%
Dividend yieldn/a
Operating marginn/a
Return on equity−26.7%
Beta to the S&P 5001.17
Volatility, annualized91.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.50−$23M
June 30, 2026n/an/a$-0.58−$15M
March 31, 2026n/an/a$-1.32−$21M
December 31, 2025n/an/a$-37.70−$24M
September 30, 2025n/an/a$-30.15−$19M
June 30, 2025n/an/a$-24.19−$16M
March 31, 2025n/an/a$-19.79−$13M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

30 ledger entries and 1 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.